Resverlogix Corp. (TSE:RVX) – Equities research analysts at Zacks Investment Research issued their Q3 2018 earnings per share estimates for Resverlogix in a research note issued to investors on Wednesday. Zacks Investment Research analyst J. Vandermosten anticipates that the biotechnology company will earn ($0.09) per share for the quarter. Zacks Investment Research also issued estimates for Resverlogix’s Q4 2018 earnings at ($0.08) EPS, FY2018 earnings at ($0.45) EPS, FY2019 earnings at ($0.35) EPS and FY2020 earnings at ($0.35) EPS.
Separately, Beacon Securities reiterated a “buy” rating on shares of Resverlogix in a research note on Wednesday, November 15th.
TRADEMARK VIOLATION WARNING: This piece was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://www.com-unik.info/2017/12/24/q3-2018-earnings-estimate-for-resverlogix-corp-rvx-issued-by-zacks-investment-research.html.
Resverlogix Corp is Canada-based clinical-stage biotechnology company. The Company is developing apabetalone (RVX-208), a molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4.
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.